![]() For companies with multiple common share classes, market capitalization includes both classes. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. Market Capitalization Reflects the total market value of a company. Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. RAPT Stock Is Rising, but Don't Call It a Meme Stock RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare ConferenceĪs the S&P 500 falters, this is what it will take to revive the bull market RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress ![]() RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit RAPT Therapeutics to Participate in Upcoming Investor Conferences RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors The story looked even better with patients experiencing a 50% improvement in EASI score - 42.9% of patients treated with RPT193 achieved this marked improvement compared to only 10% of patients in the placebo group.RAPT Therapeutics Reports Third Quarter 2021 Financial Results That was more than twice the 17% improvement seen in patients on a placebo. Patients treated with the company's experimental drug achieved a 36.3% improvement in the Eczema Area and Severity Index (EASI) score from baseline. You'd expect that RAPT's results from the early-stage study of RPT193 had to be fantastic for the biotech stock to more than double. The huge gain came after the company announced positive top-line results from a phase 1b clinical study evaluating RPT193 in treating moderate-to-severe atopic dermatitis. RAPT Therapeutics ( NASDAQ:RAPT) stock was crushing it on Monday, with shares skyrocketing 110.4% as of 11:59 a.m. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. ![]() Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2023
Categories |